Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes.

ABSTRACT

BACKGROUND: Comorbid conditions influence the survival of cancer patients. This study evaluated the influence of comorbidity on survival among lung cancer patients. METHODS: The authors evaluated the medical records of 1111 lung cancer patients of a medical center in Taiwan. Days of survival were calculated for each patient and mortality hazard ratios were estimated for associations with demographic status, comorbidity and cancer stage at diagnosis. RESULTS: On average, the survival time was slightly longer among women than among men (838±689 vs. 749±654 days, p = 0.050). Survival days increased with age (from 580±526 [≤ 50 years] to 803±693 [≥ 71 years] days, p = 0.020) and decreased with stage (from 1224±656 [stage I] to 489±536 [stage IV] days, p < 0.001). Younger patients were more likely to be diagnosed with lung cancer at a late stage. Compared with lung cancer patients without tuberculosis, those with tuberculosis had a significantly shorter average survival duration (584 vs. 791 days, p = 0.002) and a higher mortality hazard ratio (1.30, 95% CI 1.03 - 1.65). A similar trend was observed in lung cancer patients with diabetes. CONCLUSIONS: Lung cancer patients with comorbid tuberculosis or diabetes are at an elevated risk of mortality. These patients deserve greater attention while undergoing cancer treatment.